Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "IDA"

2178 News Found

Artemis Medicare Services posts Q4 FY25 consolidated PAT at Rs. 23.02 Cr
News | May 13, 2025

Artemis Medicare Services posts Q4 FY25 consolidated PAT at Rs. 23.02 Cr

The company has posted net profit of Rs. 82.62 crores for the Financial Year ended March 31, 2025

Krsnaa Diagnostics posts Q4 FY25 consolidated PAT at Rs. 20.67 Cr
News | May 13, 2025

Krsnaa Diagnostics posts Q4 FY25 consolidated PAT at Rs. 20.67 Cr

The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025

Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr
News | May 13, 2025

Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr

The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025

Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr
News | May 13, 2025

Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr

The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025

Poly Medicure posts Q4 FY25 consolidated profit at Rs. 91.83 Cr
News | May 12, 2025

Poly Medicure posts Q4 FY25 consolidated profit at Rs. 91.83 Cr

The company has posted net profit of Rs. 338.55 crores for the Financial Year ended March 31, 2025

Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr
News | May 12, 2025

Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr

The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025

Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr
News | May 12, 2025

Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr

The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025

Alembic Pharmaceuticals posts Q4 FY25 consolidated PAT at Rs. 156.63 Cr
News | May 06, 2025

Alembic Pharmaceuticals posts Q4 FY25 consolidated PAT at Rs. 156.63 Cr

The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025

OneSource Specialty Pharma reports consolidated Q4 FY25 PAT at Rs. 98.50 Cr
News | May 06, 2025

OneSource Specialty Pharma reports consolidated Q4 FY25 PAT at Rs. 98.50 Cr

The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025

Tatva Chintan Pharma Chem reports consolidated Q4 FY25 PAT at Rs. 1.03 Cr
News | May 05, 2025

Tatva Chintan Pharma Chem reports consolidated Q4 FY25 PAT at Rs. 1.03 Cr

The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025

Latest Stories

Lupin launches Dasatinib tablets in US, eyes $930 million oncology market

Artemis Medicare reports strong Q3 growth: revenue up 17%, net profit up 8%

Lupin & TB Alliance team up to push groundbreaking TB drug forward

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging